CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 49 enrolled
Drug / intervention
Norflo Oro +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03584724
NCT03584724Early Ph 1Completed
CompareCT.gov

Assessment of the Anti-inflammatory Effects of Norflo Oro in Acute Relapses of HLA-B27 Associated Autoimmune Uveitis: a Multicenter Randomized, Placebo Controlled, Double-blind Clinical Study

Eye Pharma·interventional·Posted Jul 12, 2018·Updated Mar 28, 2022

In Brief

A Early Phase 1 clinical trial evaluating Norflo Oro and Placebo for Norflo Oro for Uveitis. Completed, enrolled 49 participants across 1 site.

Detailed Summary

The purpose of this study is to explore the efficacy of Norflo Oro in the treatment of relapsing autoimmune uveitis (RAU), measured as a long term reduction of the frequency and the severity of relapses, in patients with HLA-B27 associated uveitis, under conditions of routine medical practice. The reduction of the mean number of relapses per patient between the year before study treatment and the study period will also be assessed.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUveitis
CountriesUnited States
CollaboratorsBascom Palmer Eye Institute

Timeline

Early Ph 1CompletedFinished
20192020202120222023202420252026
First PostedJul 12, 2018
Enrollment StartDec 19, 2018
Primary CompletionAug 20, 2020
Study CompletionDec 30, 2020
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 8.0 years ago

Interventions

Norflo Orodrug

Norflo Oro is highly bioavailable curcumin complexed into phytosomes

Placebo for Norflo Orodrug

Placebo consist of look-alike single foil pouches without active ingredient of Norflo.